Replimune (REPL) Research & Development (2017 - 2026)
Replimune (REPL) reported Research & Development of $49.28 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 14.8% from $57.84 million a year earlier and down 5.8% from the prior quarter.
Replimune (REPL) Research & Development (2017 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Replimune's Research & Development came in at $212.62 million, up 4.6% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $221.18 million, up 16.8% from FY2025.
- Research & Development has increased for nine consecutive fiscal years, with a five-year compound annual growth rate of 31.3% (FY2021 to FY2026).
- By fiscal year, Research & Development came in at $189.45 million in FY2025 (+8.3%), $174.96 million in FY2024 (+38.3%), $126.53 million in FY2023 (+59.1%) and $79.55 million in FY2022 (+40.2%).
- The fiscal Q1 2027 figure ranks as the lowest quarterly Research & Development since fiscal Q3 2025.
- Year over year, Research & Development gained in five of the last eight quarters, with growth averaging 11.0%.
- The high point for year-over-year Research & Development in five years was fiscal Q4 2023 (growth of 74.6%); the low point was fiscal Q1 2027 (a decline of 14.8%).
- Per Business Quant data, the three fiscal quarters before Q1 2027 came in at $52.32 million (Q4 2026), $53.14 million (Q3 2026) and $57.88 million (Q2 2026).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Replimune | 1.05 Bn | 1.05 Bn | - | 49.28 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.28 Mn |
| Mar 31, 2026 | 52.32 Mn |
| Dec 31, 2025 | 53.14 Mn |
| Sep 30, 2025 | 57.88 Mn |
| Jun 30, 2025 | 57.84 Mn |
| Mar 31, 2025 | 53.98 Mn |
| Dec 31, 2024 | 48.00 Mn |
| Sep 30, 2024 | 43.45 Mn |
| Jun 30, 2024 | 42.97 Mn |
| Mar 31, 2024 | 42.58 Mn |
| Dec 31, 2023 | 42.85 Mn |
| Sep 30, 2023 | 49.10 Mn |
| Jun 30, 2023 | 40.44 Mn |
| Mar 31, 2023 | 37.95 Mn |
| Dec 31, 2022 | 30.26 Mn |
| Sep 30, 2022 | 28.83 Mn |
| Jun 30, 2022 | 29.48 Mn |
| Mar 31, 2022 | 21.74 Mn |
| Dec 31, 2021 | 19.35 Mn |
| Sep 30, 2021 | 19.90 Mn |
Replimune Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=REPL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "REPL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=REPL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();